{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:14:28Z","timestamp":1782368068350,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcpo.2026.100718","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:21:54Z","timestamp":1771226514000},"page":"100718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Economic value, affordability, and scale-up of adjuvant immunotherapies in lung cancer treatment: From cost-effectiveness decision to budget impact analysis"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9788-1868","authenticated-orcid":false,"given":"Rashidul Alam","family":"Mahumud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padam Kanta","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Shahjalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khorshed","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2026.100718_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jcpo.2026.100718_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jcpo.2026.100718_bib3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcpo.2026.100718_bib4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jcpo.2026.100718_bib5","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100718_bib6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/annonc\/mdx110","article-title":"Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund","volume":"28","author":"Aggarwal","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2026.100718_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers17101722","article-title":"Optimising cancer medicine in clinical practices: are neoadjuvant and adjuvant immunotherapies affordable for cancer patients in low- and middle-income countries?","volume":"17","author":"Mahumud","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcpo.2026.100718_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis - principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Heal"},{"key":"10.1016\/j.jcpo.2026.100718_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jval.2022.07.006","article-title":"Cost-effectiveness and budget impact of future developments with whole-genome sequencing for patients with lung cancer","volume":"26","author":"Simons","year":"2023","journal-title":"Value Heal"},{"key":"10.1016\/j.jcpo.2026.100718_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104195","article-title":"Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: a comprehensive overview","volume":"193","author":"Wu","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jcpo.2026.100718_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-023-09727-7","article-title":"Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Health Serv. Res"},{"key":"10.1016\/j.jcpo.2026.100718_bib12","article-title":"Real-world effectiveness and cost-utility analysis of second-line immunotherapy for non-oncogene-addicted advanced non-small cell lung cancer","volume":"51","author":"Sawasdisara","year":"2026","journal-title":"Value Heal Reg. Issues"},{"key":"10.1016\/j.jcpo.2026.100718_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-12043-w","article-title":"Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review","volume":"24","author":"Cheng","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jcpo.2026.100718_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0238536","article-title":"Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: a systematic review","volume":"15","author":"Ding","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jcpo.2026.100718_bib15","article-title":"Cost-effectiveness of pembrolizumab for the treatment of non\u2013small-cell lung cancer: a systematic review","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.jcpo.2026.100718_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost- effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jcpo.2026.100718_bib17","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcpo.2026.100718_bib18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jval.2023.04.004","article-title":"Developing criteria for health economic quality evaluation tool","volume":"26","author":"Kim","year":"2023","journal-title":"Value Heal"},{"key":"10.1016\/j.jcpo.2026.100718_bib19","author":"International Monetary Fund","year":"2025","journal-title":"Int. Financ. Stat."},{"key":"10.1016\/j.jcpo.2026.100718_bib20","series-title":"Consumer Price Index databases","author":"U.S. Bureau of Labor Statistics","year":"2024"},{"key":"10.1016\/j.jcpo.2026.100718_bib21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40273-016-0426-8","article-title":"A methodological review of us budget-impact models for new drugs","volume":"34","author":"Mauskopf","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jcpo.2026.100718_bib22","unstructured":"World Bank. World Development Indicators: Purchasing Power Parities and Related Indicators. Washington, DC: World Bank."},{"key":"10.1016\/j.jcpo.2026.100718_bib23","series-title":"Purchasing Power Parities (PPP) Statistics","author":"OECD","year":"2025"},{"key":"10.1016\/j.jcpo.2026.100718_bib24","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1097\/CM9.0000000000000536","article-title":"First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China","volume":"132","author":"Li","year":"2019","journal-title":"Chin. Med J. (Engl. )"},{"key":"10.1016\/j.jcpo.2026.100718_bib25","first-page":"1","article-title":"First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis and cost-effectiveness analysis","volume":"11","author":"Zhu","year":"2023","journal-title":"Front Public Heal"},{"key":"10.1016\/j.jcpo.2026.100718_bib26","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/cam4.2793","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC","volume":"9","author":"Wan","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jcpo.2026.100718_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2018.08.018","article-title":"Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer","volume":"124","author":"Georgieva","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jcpo.2026.100718_bib28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/13696998.2021.1917139","article-title":"Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data","volume":"24","author":"Chaudhary","year":"2021","journal-title":"J. Med Econ."},{"key":"10.1016\/j.jcpo.2026.100718_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081270","article-title":"Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II\u2013IIIA EGFR-mutated non-small cell lung cancer in China","volume":"14","author":"Mu","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40273-017-0527-z","article-title":"Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of pd-l1 in the United States","volume":"35","author":"Huang","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jcpo.2026.100718_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.01649","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer","volume":"10","author":"Hu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jcpo.2026.100718_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40261-019-00869-3","article-title":"Nivolumab versus docetaxel for previously treated advanced non-small cell lung cancer in china: a cost-effectiveness analysis","volume":"40","author":"Liu","year":"2020","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.jcpo.2026.100718_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non\u2013small cell lung cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib34","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11096-020-01076-3","article-title":"Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer","volume":"42","author":"Lin","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.jcpo.2026.100718_bib35","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2217\/imt-2019-0178","article-title":"Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA","volume":"11","author":"Huang","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jcpo.2026.100718_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40258-018-0452-0","article-title":"Modelled economic evaluation of nivolumab for the treatment of second-line advanced or metastatic squamous non-small-cell lung cancer in Australia using both partition survival and markov models","volume":"17","author":"Gao","year":"2019","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.jcpo.2026.100718_bib37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13696998.2019.1590842","article-title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","volume":"22","author":"Ondhia","year":"2019","journal-title":"J. Med Econ."},{"key":"10.1016\/j.jcpo.2026.100718_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2024-083895","article-title":"Cost-effectiveness of consolidation durvalumab for inoperable stage III non-small cell lung cancer in Vietnam","volume":"14","author":"Mai","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.803626","article-title":"Cost-effectiveness of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy in metastatic non-squamous and squamous nsclc patients with pd-l1 expression \u2265 50","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.jcpo.2026.100718_bib40","first-page":"273","article-title":"Economic evaluation of nivolumab versus docetaxel for the treatment of advanced squamous and non-squamous non-small cell lung cancer after prior chemotherapy in China","volume":"7","author":"Hu","year":"2023","journal-title":"Pharm. Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib41","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1002\/cam4.5440","article-title":"Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer","volume":"12","author":"Cheng","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.jcpo.2026.100718_bib42","article-title":"Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: a sequential model","volume":"11","author":"Zhao","year":"2023","journal-title":"Front Public Heal"},{"key":"10.1016\/j.jcpo.2026.100718_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40261-022-01157-3","article-title":"Cost-effectiveness analysis of atezolizumab versus durvalumab as first-line treatment of extensive-stage small-cell lung cancer in the USA","volume":"42","author":"Ionova","year":"2022","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.jcpo.2026.100718_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2024.1256992","article-title":"Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector\u2019s and societal perspectives","volume":"15","author":"Gan","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.jcpo.2026.100718_bib45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2019.10.017","article-title":"Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater","volume":"138","author":"She","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jcpo.2026.100718_bib46","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1080\/13696998.2020.1775620","article-title":"Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer","volume":"23","author":"Aziz","year":"2020","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jcpo.2026.100718_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.760686","article-title":"Cost-effectiveness of nivolumab plus ipilimumab with and without chemotherapy for advanced non-small cell lung cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jcpo.2026.100718_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020128","article-title":"OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer","volume":"8","author":"Wen","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2019.11952","article-title":"Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer in the United States","volume":"2","author":"Criss","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12094-017-1715-1","article-title":"Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer","volume":"20","author":"Zheng","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.jcpo.2026.100718_bib51","first-page":"1061","article-title":"First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China","volume":"21","author":"Yang","year":"2021","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"key":"10.1016\/j.jcpo.2026.100718_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4223-y","article-title":"Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer\u2019s perspective","volume":"18","author":"Tan","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jcpo.2026.100718_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031019","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA","volume":"9","author":"Zeng","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib54","article-title":"Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China","volume":"10","author":"Shao","year":"2022","journal-title":"Front Public Heal"},{"key":"10.1016\/j.jcpo.2026.100718_bib55","first-page":"1","article-title":"Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.jcpo.2026.100718_bib56","article-title":"Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC","volume":"10","author":"Chen","year":"2022","journal-title":"Front Public Heal"},{"key":"10.1016\/j.jcpo.2026.100718_bib57","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3111\/13696998.2016.1151432","article-title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: A comparison of modeling approaches to estimate and extrapolate survival outcomes","volume":"19","author":"Goeree","year":"2016","journal-title":"J. Med Econ."},{"key":"10.1016\/j.jcpo.2026.100718_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.lungcan.2022.11.008","article-title":"Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC","volume":"174","author":"Chen","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jcpo.2026.100718_bib59","article-title":"Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China","volume":"10","author":"Li","year":"2022","journal-title":"Front Public Heal"},{"key":"10.1016\/j.jcpo.2026.100718_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081270","article-title":"Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China","volume":"14","author":"Mu","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13696998.2019.1590842","article-title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","volume":"22","author":"Ondhia","year":"2019","journal-title":"J. Med Econ."},{"key":"10.1016\/j.jcpo.2026.100718_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non\u2013small cell lung cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2026.100718_bib63","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40258-018-0452-0","article-title":"Modelled economic evaluation of nivolumab for the treatment of second-line advanced or metastatic squamous non-small-cell lung cancer in Australia using both partition survival and markov models","volume":"17","author":"Gao","year":"2019","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.jcpo.2026.100718_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-083895","article-title":"Cost-effectiveness of consolidation durvalumab for inoperable stage III non-small cell lung cancer in Vietnam","volume":"14","author":"Mai","year":"2024","journal-title":"BMJ Open"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:53:09Z","timestamp":1772923989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326000184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":64,"alternative-id":["S2213538326000184"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100718","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic value, affordability, and scale-up of adjuvant immunotherapies in lung cancer treatment: From cost-effectiveness decision to budget impact analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100718"}}